

In the Specification:

Please add the following section to page 1 of the application:

-- CROSS REFERENCE TO RELATED APPLICATIONS

This Application is a continuation of International Application No. PCT/US02/27247, filed August 26, 2002, which claims priority to U.S. Provisional Application No. 60/314,837, filed August 24, 2001, all of which are incorporated by reference herein as if set forth in their entirety. --

Please add the following section after page 61 of the application:

----- ABSTRACT -

The present invention relates to the discovery that non-traditional export of certain pro-inflammatory cytokines lacking a signal sequence from a cell can be inhibited by copper chelation and/or administration to the cell of a truncated form of S100A13 lacking the basic residue portion. Further, copper chelation inhibits, *inter alia*, neointima formation, macrophage infiltration and associated inflammation, cell proliferation, secretion of extracellular matrix, intimal thickening, adventitial angiogenesis, restenosis, and the like, associated with vascular vessel injury. Thus, the present invention provides novel methods of preventing and treating, and for identifying novel compounds also useful as therapeutics for, such conditions. --